Academic participation in nanomedicine research is welcomed by European industries. The recipe for success may or may not include creativity, but it will certainly require awareness of drug development and approval processes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
NOBUHIRO NISHIYAMA
References
Webster. R. et al. Drug Metab. Disp. 35, 9–16 (2007).
Owens, J. Nature Rev. Drug Discov. 6, 99–101 (2007).
Nishiyama, N. et al. Nature Mater. 4, 934–941 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eaton, M. Nanomedicine: Industry-wise research. Nature Mater 6, 251–253 (2007). https://doi.org/10.1038/nmat1879
Issue Date:
DOI: https://doi.org/10.1038/nmat1879
This article is cited by
-
How does regulatory uncertainty shape the innovation process? Evidence from the case of nanomedicine
The Journal of Technology Transfer (2022)
-
Stimulus-responsive polymeric nanoparticles for biomedical applications
Science China Chemistry (2010)
-
Regulating nanomedicine
Nature Materials (2007)
